NCT04394234View on ClinicalTrials.gov

A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants

CompletedOBSERVATIONAL

Enrollment

961,985

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions

Uterine Hemorrhage

Interventions

DRUG

Direct oral anticoagulant (DOACs)

Data of participants newly exposed to individual DOACs that is rivaroxaban, apixaban, dabigatran from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.

DRUG

Warfarin

Data of participants newly exposed to warfarin from 19-Oct-2010 to 31-Dec-2018 will be assessed. No study drug treatment will be administered as part of this observational study.

Trial Locations (1)

08560

Janssen R&D, Titusville

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT04394234 - A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants | Biotech Hunter | Biotech Hunter